A phase 1/2 dose escalation trial of multiple doses of MLN2704 (DM1 conjugated monoclonal antibody MLN591) in subjects with metastatic androgen-independent prostate cancer
Phase of Trial: Phase I/II
Latest Information Update: 12 Jul 2007
At a glance
- Drugs MLN 2704 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Jul 2007 Status changed from in progress to completed.
- 01 Oct 2005 New trial record.